Peer-reviewed report on Moderna COVID-19 vaccine publishes (nih.gov)

nih.gov

The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).

Submitted by Admin on Wed, 12/30/2020 - 19:21
cnn.com

(CNN)The US Food and Drug Administration has authorized the first Covid-19 vaccine for emergency use in the United States. Millions of doses of the Pfizer and BioNTech coronavirus vaccine, which has been found to be 95% effective, will be soon shipped around the country so vaccinations can begin within days.

Submitted by mo2 on Sat, 12/12/2020 - 21:03
npr.org

One of the experimental drugs that President Trump received while he was battling the coronavirus has been approved for emergency use by the Food and Drug Administration. The drug, made by the biotech company Regeneron, is the second antibody treatment to win emergency use approval from the FDA.

The treatment combines two antibodies — casirivimab and imdevimab — and administers them together by IV. In a clinical trial of about 800 people, the combination was shown to significantly reduce virus levels within days of treatment.

Submitted by mo2 on Sun, 11/22/2020 - 20:59
reuters.com

(Reuters) - Moderna Inc’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second U.S. drugmaker to report results that far exceed expectations.

Together with Pfizer Inc’s vaccine, which is also more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available this year.

Submitted by mo2 on Mon, 11/16/2020 - 20:55

One in 5 COVID-19 patients develop mental illness within 90 days -study (reuters.com)

LONDON, Nov 9 (Reuters) - Many COVID-19 survivors are likely to be at greater risk of developing mental illness, psychiatrists said on Monday, after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.

Anxiety, depression and insomnia were most common among recovered COVID-19 patients in the study who developed mental health problems, and the researchers also found significantly higher risks of dementia, a brain impairment condition.

Submitted by Admin on Wed, 11/11/2020 - 18:09

Here's who's on President-elect Biden's newly formed Transition Covid-19 Advisory Board (cnn.com)

cnn.com

(CNN)President-elect Joe Biden and Vice President-elect Kamala Harris' newly appointed Transition Covid-19 Advisory Board is led by established public health officials and staffed by a mix of doctors and current and former government officials, some with high-profile media visibility.

Submitted by Admin on Wed, 11/11/2020 - 18:05